A cost-effective approach to administering palivizumab in a centralised nurse-led community clinic

Archives of Disease in Childhood

Volumn 93, Issue 7, 2008, Pages 638-

  Marshall, L ^a   Kelsall, W ^b   Gooding, N ^b  

^a Cambridgeshire PCT   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; LETTER; NURSE; NURSING; OUTPATIENT DEPARTMENT; OXYGEN THERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; COMMUNITY CARE; COMMUNITY HEALTH NURSING; COST BENEFIT ANALYSIS; ECONOMICS; INFANT; NEWBORN; STATISTICS; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COMMUNITY HEALTH NURSING; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; DRUG COSTS; ENGLAND; HUMANS; INFANT; INFANT, NEWBORN;

EID: 48949119126     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.130138     Document Type: Letter

References (4)

1. Joint Committee on Vaccination and Immunisation. Minutes of the JCVI RSV sub-group on Thursday, 11 November 2004. http://www. advisorybodies.doh.gov.uk/jcvi/mins111104rvi.htm (accessed 27 March 2008).
2. Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003;13:420-23.
3. Coffman S, Peck J, Rasmussen CS. Developing a Synagis clinic for synctial virus prophylaxis. MCN Am J Matern Child Nurs 2001;26(5):246.
4. Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch Dis Child 2006;91:717.